Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.

Maria Laura CanaleAndrea CameriniGiancarlo CasoloAlessio LilliIrma BiscegliaIris ParriniChiara LestuzziJacopo Del MeglioCheti PuccettiLara CameriniDomenico AmorosoNicola Maurea

Published in: Advances in therapy (2020)

Our findings confirm pericardial effusion as a relatively frequent side effect of immunotherapy in NSCLC. Clinicians should be aware of this specific toxicity in patients with metastatic NSCLC receiving immunotherapy and refer to a cardiologist for a multidisciplinary approach.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
oxidative stress
risk factors
palliative care
tyrosine kinase